Phase II Data on Paclitaxel and Docetaxel in Gastrointestinal Malignancies

  • M. S. Aapro
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 142)

Abstract

From the contributions in this volume, it is apparent that in spite of promising chemotherapy combinations and new multidisciplinary approaches, the treatment of advanced gastrointestinal malignancies remains a difficult task. New agents have recently been developed with either a better therapeutic ratio (fluoropyrimidine analogs or modulators of the metabolic pathway of those agents) or a better activity due to a different mechanism of action. Among the latter agents, the topoisomerase I inhibitors (especially irinotecan, also known as CPT-11) and new antimetabolities (difluorodeoxycytidine, also known as gemcitabine) are of interest for difficult tumors, such as colon and pancreatic cancer. This short review describes the phase II studies on the activity of taxoids, agents that promote tubulin assembly in microtubules and inhibit their depolymerization.

Keywords

Adenocarcinoma Oncol Paclitaxel Gravel Docetaxel 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abruzzese JL, Evans D, Gravel D et al (1995) Docetaxel, a potentially active agent for patients with pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 14: 221Google Scholar
  2. Ajani JA, Ilson DH, Daugherty K et al (1994) Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86: 1086–1091PubMedCrossRefGoogle Scholar
  3. Braakbuis BJM, Hill BT, Dietel M et al (1994) In vitro antiproliferative activity of docetaxel, paclitaxel and cisplatin against human tumors and normal bone marrow cells. Anticancer Res 14: 205–208Google Scholar
  4. Brown T, Tangen C, Fleming T et al (1993) A phase II trial of Taxol and granulocyte colony stimulating factor in patients with adenocarcinoma of the pancreas. Proc Am Soc Clin Oncol 13: 200Google Scholar
  5. Clark T, Kemeny N, Conti JA et al (1994) Phase II trial of docetaxel in previously untreated patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 13: 212Google Scholar
  6. Einzig AI, Wiernik PH, Lipsitz S et al (1993) Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract: the Eastern Cooperative Group results. Proc Am Soc Clin Oncol 12: 194Google Scholar
  7. Einzig AI, Lipshitz S, Wiernik PH et al (1995) Phase II trial of taxotere in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with chemotherapy. The ECOG results. Proc Am Soc Clin Oncol 14: 191Google Scholar
  8. Hanauske A, Degen D, Hilsenbeck SG et al (1992) Effects of taxotere and taxol on in vitro colony formation of freshly explanted tumor cells. Anticancer Drugs 3: 121–124PubMedCrossRefGoogle Scholar
  9. Lavelle F, Bissery MC,Combeau C et al (1995) Preclinical evaluation of docetaxel (tacotere). Semin Oncol 22:2 [Suppl 4]:3–16Google Scholar
  10. Pazdur R, Kudelka AP, Kavanagh JJ et al (1993) The taxoids: Paclitaxel and docetaxel. Cancer Treat Rev 19: 351–356Google Scholar
  11. Pazdur R, Lasserre Y, Soh LT et al (1994) Phase II trial of docetaxel in metastatic colorectal carcinoma. Ann Oncol 5: 468–470PubMedGoogle Scholar
  12. Rougier P, de Forni M, Adenis A et al (1994) Phase II study of Taxotere (RP 56976, docetaxel) in pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 13: 200Google Scholar
  13. Rowinsky EK, Onetto N, Canetta RM et al (1992) Taxol: the first of the taxanes, an important class of antitumor agents. Semin Oncol 19: 646–662PubMedGoogle Scholar
  14. Sternberg CN, ten Bokkel Huinink WW, Smyth JF et al (1994) Docetaxel, a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group study. Br J Cancer 70: 376–379PubMedCrossRefGoogle Scholar
  15. Sulkes A, Smyth J, Sessa C et al (1994) Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 70: 380–383PubMedCrossRefGoogle Scholar
  16. Taguchi T (1994) An early phase II study of RP 56976 (docetaxel) in patients with cancer of the gastrointestinal tract. Gan To Kagaku Ryoho 21: 2431–2437PubMedGoogle Scholar
  17. Vaughn DJ, Shaw LM, Recio A et al (1995). A phase II trial of 96-hour infusional paclitaxel with pharmacokinetic analysis in metastatic colorectal cancer. Proc Am Soc Clin Oncol 15: 530Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • M. S. Aapro
    • 1
  1. 1.Division of Medical OncologyEuropean Institute of OncologyMilanoItaly

Personalised recommendations